MA30496B1 - Derives de 2-alcoxy -3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation - Google Patents

Derives de 2-alcoxy -3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation

Info

Publication number
MA30496B1
MA30496B1 MA31444A MA31444A MA30496B1 MA 30496 B1 MA30496 B1 MA 30496B1 MA 31444 A MA31444 A MA 31444A MA 31444 A MA31444 A MA 31444A MA 30496 B1 MA30496 B1 MA 30496B1
Authority
MA
Morocco
Prior art keywords
preparation
compositions containing
alcoxy
trihydroxy
containing same
Prior art date
Application number
MA31444A
Other languages
English (en)
Inventor
Jidong Zhang
Yannick Benedetti
Alain Commercon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA30496B1 publication Critical patent/MA30496B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne notamment des dérivés de 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur préparation, des compositions les contenant, et leur utilisation comme médicament, en particulier en tant qu'agents anticancéreux.
MA31444A 2006-05-24 2008-12-05 Derives de 2-alcoxy -3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation MA30496B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0604736A FR2901556A1 (fr) 2006-05-24 2006-05-24 Derives de 2-alcoxy-3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
MA30496B1 true MA30496B1 (fr) 2009-06-01

Family

ID=37561171

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31444A MA30496B1 (fr) 2006-05-24 2008-12-05 Derives de 2-alcoxy -3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation

Country Status (24)

Country Link
US (1) US7994161B2 (fr)
EP (1) EP2029555A2 (fr)
JP (1) JP2009537616A (fr)
KR (1) KR20090010215A (fr)
CN (1) CN101454296B (fr)
AR (1) AR061105A1 (fr)
AU (1) AU2007253198A1 (fr)
BR (1) BRPI0712264A2 (fr)
CA (1) CA2649685A1 (fr)
CR (1) CR10390A (fr)
DO (1) DOP2007000105A (fr)
EA (1) EA200870567A1 (fr)
EC (1) ECSP088899A (fr)
FR (1) FR2901556A1 (fr)
GT (1) GT200800252A (fr)
IL (1) IL195053A0 (fr)
MA (1) MA30496B1 (fr)
MX (1) MX2008015003A (fr)
NO (1) NO20085267L (fr)
PE (1) PE20080099A1 (fr)
TN (1) TNSN08411A1 (fr)
TW (1) TW200812981A (fr)
UY (1) UY30367A1 (fr)
WO (1) WO2007135295A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878525B1 (fr) 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477464A (en) * 1983-02-10 1984-10-16 Ciba-Geigy Corporation Hetero-benzazepine derivatives and their pharmaceutical use
US4692522A (en) 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4831135A (en) 1986-06-18 1989-05-16 The Regents Of The University Of California Bengamide anthelmintics
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
GB9411841D0 (en) 1994-06-14 1994-08-03 Pharma Mar Sa New antitumoral compounds from jaspis sponge
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
US6239127B1 (en) 1999-11-17 2001-05-29 Novartis Ag Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation
CO5140099A1 (es) * 1998-11-17 2002-03-22 Novartis Ag Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
CN1191237C (zh) 2000-05-11 2005-03-02 诺瓦提斯公司 取代的己内酰胺碳酸酯与醚和它们作为抗肿瘤剂的用途
EP1337854A2 (fr) 2000-11-14 2003-08-27 Novartis AG Methode de criblage de composes antiproliferatifs et methode permettant d'inhiber une croissance tumorale
US6545148B2 (en) 2001-03-12 2003-04-08 Novartis Ag Process for preparing certain substituted caprolactams
JP2004262793A (ja) 2003-02-28 2004-09-24 Noyaku Bio Technology Kaihatsu Gijutsu Kenkyu Kumiai 化合物ｎ−９０１１、その製造法及び用途
JP2006528611A (ja) * 2003-07-25 2006-12-21 ノバルティス アクチエンゲゼルシャフト 置換ラクタムおよびそれらの抗がん剤としての使用
US7153846B2 (en) 2003-10-24 2006-12-26 Sanofi-Aventis Deutschland Gmbh Bengamide derivatives, process for preparing them, and their use
DE10349669B3 (de) 2003-10-24 2005-05-25 Aventis Pharma Deutschland Gmbh Bengamide-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
FR2878525B1 (fr) 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation

Also Published As

Publication number Publication date
BRPI0712264A2 (pt) 2012-01-17
CA2649685A1 (fr) 2007-11-29
TNSN08411A1 (en) 2010-04-14
IL195053A0 (en) 2009-08-03
PE20080099A1 (es) 2008-03-31
EA200870567A1 (ru) 2009-06-30
US7994161B2 (en) 2011-08-09
MX2008015003A (es) 2008-12-09
AR061105A1 (es) 2008-08-06
WO2007135295A3 (fr) 2008-01-10
AU2007253198A1 (en) 2007-11-29
CN101454296B (zh) 2011-11-09
GT200800252A (es) 2009-03-13
US20090075971A1 (en) 2009-03-19
NO20085267L (no) 2009-02-23
DOP2007000105A (es) 2007-11-15
ECSP088899A (es) 2008-12-30
CN101454296A (zh) 2009-06-10
JP2009537616A (ja) 2009-10-29
EP2029555A2 (fr) 2009-03-04
CR10390A (es) 2009-01-09
FR2901556A1 (fr) 2007-11-30
KR20090010215A (ko) 2009-01-29
UY30367A1 (es) 2008-01-02
WO2007135295A2 (fr) 2007-11-29
TW200812981A (en) 2008-03-16

Similar Documents

Publication Publication Date Title
MA30410B1 (fr) Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique.
MA29480B1 (fr) Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
MA30765B1 (fr) Derives innovants du thiophene
TNSN07167A1 (fr) Indoles substitues, compositions les contenant, procede de fabrication et utilisation
PT1274687E (pt) Derivados de 1,2,3,4-tetra-hidroisoquinolina
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
TW200639173A (en) Substituted pyrazolopyridines, compositions containing same, manufacturing process therefor and use thereof
MA30221B1 (fr) Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MA29652B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
TN2012000146A1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MEP8509A (en) Combination treatment for diabetes mellitus
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
MA29264B1 (fr) Pyroles et imidazoles substitues, compositions les contenant, procede de fabrication et utilisation
MA30042B1 (fr) Composes calcilytiques
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
MA29248B1 (fr) Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
MA29910B1 (fr) Potentialisateurs des recepteurs ampa
MA30496B1 (fr) Derives de 2-alcoxy -3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation
ATE539045T1 (de) Parfümierungsbestandteile des holzigen typs
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments